# Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

> Research article (Emerging Microbes & Infections, 2022) · cited 44× · AI/ML

**Wikidata**: [openalex:W4281716282](https://www.wikidata.org/wiki/openalex:W4281716282)  
**Source**: https://4ort.xyz/entity/efficacy-of-heterologous-boosting-against-sars-cov-2-using-a-recombinant-interferon-armed-fusion-protein-vaccine-v-01-a-